Sunshine Biopharma (SBFM) Set to Post Quarterly Earnings on Thursday

Sunshine Biopharma (NASDAQ:SBFM) is projected to announce its results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($3.40) per share and revenue of $9.60 million for the quarter.

Sunshine Biopharma (NASDAQ:SBFM) last posted its earnings results on Thursday, August 13th. The company reported ($23.00) EPS for the quarter, beating the consensus estimate of ($24.00) by $1.00. Sunshine Biopharma had a negative return on equity of 26.36% and a negative net margin of 17.94%. The firm had revenue of $9.26 million during the quarter, compared to the consensus estimate of $8.70 million. On average, analysts expect Sunshine Biopharma to post ($39.00) EPS for the current fiscal year and ($8.00) EPS for the next fiscal year.

Sunshine Biopharma Trading Up 3.6%

Shares of SBFM stock opened at $2.85 on Wednesday. The business’s 50-day moving average price is $11.25 and its 200-day moving average price is $100.82. Sunshine Biopharma has a 12 month low of $2.53 and a 12 month high of $464.00. The firm has a market capitalization of $627,000.00, a price-to-earnings ratio of -0.01 and a beta of 1.32.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Weiss Ratings raised Sunshine Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 28th. Wall Street Zen upgraded shares of Sunshine Biopharma to a “hold” rating in a research report on Saturday, October 31st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sunshine Biopharma has an average rating of “Reduce”.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors. In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.